CYP19A1 and breast carcinoma: By using ToxPi metrics, we confirmed the previous assumption that CBD is the best cannabinoid when the simultaneous action towards aromatase, ER, and AR is considered, which highlights its therapeutic potential for ER+ breast cancer.